A study of pulmonary function test in type II diabetes mellitus: spirometry based by Suguna, S
 A STUDY OF PULMONARY FUNCTION TEST IN TYPE 
II DIABETES MELLITUS – SPIROMETRY BASED 
 
 
Dissertation submitted to 
THE TAMILNADU Dr. M. G. R MEDICAL UNIVERSITY 
In partial fulfillment of the 
regulations for the award of the degree of 
 
M.D. (PHYSIOLOGY) 
BRANCH-V 
 
 
 
 
 
 
THANJAVUR MEDICAL COLLEGE AND HOSPITAL 
THE TAMIL NADU Dr. M.G.R MEDICAL UNIVERSITY 
CHENNAI, INDIA 
APRIL 2013 
 
 CERTIFICATE 
This is to certify that this Dissertation entitled “A STUDY OF 
PULMONARY FUNCTION TEST IN TYPE II DIABETES MELLITUS – 
SPIROMETRY BASED” is submitted to the Tamilnadu Dr. M.G.R 
Medical University, Chennai which was done under the guidance of our 
Professor Dr.R.Vinodha M.D., Professor and HOD, Department of Physiology, 
Thanjavur Medical College, Thanjavur. 
 
This dissertation is a record of fresh work done by the candidate 
Dr.S.Suguna during the course of the study (2010-2013). This work was carried 
out by the candidate herself under my supervision.  
 
 
 
DR. C.GUNASEKARAN,M.D.,DCH       DR. R.VINODHA M.D., 
The Dean                                                      Professor and Head of the Department          
 Thanjavur Medical College                          Department of Physiology 
Thanjavur - 613004                                      Thanjavur Medical College 
                                                                     Thanjavur - 613004 
 
 
 
 DECLARATION 
 
I hereby declare that this dissertation entitled “A study of pulmonary 
function test in type II diabetes mellitus – Spirometry based” is a bonafide 
and genuine research work done by me under the guidance of our Professor 
Dr.R.Vinodha M.D., Professor and Head of Department, Department of 
Physiology, Thanjavur Medical College, Thanjavur. 
 
This dissertation is submitted to the Tamilnadu Dr. M.G.R Medical 
University, Chennai in partial fulfillment of the university requirements for the 
award of degree M.D in physiology. 
 
 
Place: 
Date:                                                                              (Dr.S.Suguna) 
 
 
 
 
 
 
 
 
 
 
 ACKNOWLEDGEMENT 
 
I express my deep sense of gratitude to my teacher and guide Professor 
Dr.R.Vinodha M.D., Professor and Head of Department, Department of 
Physiology, Thanjavur Medical College, Thanjavur, for her valuable 
suggestion and excellent guidance throughout the period of my study. 
Our Professor has been always inspiring me and without her inspiration 
and encouragement this dissertation would have never been a complete one. 
I express my gratitude to the Dean, Thanjavur Medical College for 
allowing me to pursue this dissertation work. 
I sincerely thank HOD of Diabetology for permitting me to carry out the 
study in the outpatient department of diabetes. 
I also thank HOD of biochemistry for permitting me to carry out the 
biochemical evaluations in their department. 
I express my thanks and gratitude to all my patients who co-operated to 
undergo the study 
 
 
 
 
 
 
  
 
S.NO 
 
CONTENTS 
 
PAGE NO 
 
1. 
 
INTRODUCTION                           
 
1 
 
2. 
 
AIMS & OBJECTIVES 
 
3 
 
3. 
 
REVIEW OF LITERATURE 
 
4 
 
4. 
 
MATERIALS & METHODS 
 
48 
 
5. 
 
RESULTS 
 
53 
 
6. 
 
DISCUSSION 
 
71 
 
7. 
 
CONCLUSION 
 
79 
 
8. 
 
BIBLIOGRAPHY 
 
 
9. 
 
ANNEXURE 
 
 
 
 
  
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
  
INTRODUCTION 
 
           
Diabetes mellitus is one of the most common chronic diseases in nearly 
all countries, and continues to increase in numbers and significance, as 
changing lifestyles lead to reduced physical activity, and increased obesity (1). 
According to WHO survey, India will be the world diabetic capital in 
2025. As the prevalence of diabetes is increasing, with type II diabetes 
accounting for 90 – 95% of all cases (2). It is often asymptomatic in its early 
stages and can remain undiagnosed for many years. 
The etiogenesis of type II diabetes reflects the heterogeneous genetic, 
pathologic, environmental and metabolic abnormalities that can exist in 
different patients and all lead to a final common pathway of hyperglycemia (3). 
Chronic hyperglycemia is associated with continuing damage, dysfunction and 
failure of various organs, especially the eyes, kidneys, nerves, heart, lungs and 
blood vessels (4). 
The pathogenesis is thought to involve both a microangiopathic process 
and non enzymatic glycosylation of tissue proteins. This process results in 
impaired collagen and elastin cross-linkage with a reduction in strength and 
elasticity of connective tissue. Due to the presence of an abundant connective 
tissue and an extensive microvascular circulation raises the possibility that lung 
may be a target organ in diabetic patients (5). 
  It has been demonstrated that pulmonary complications in diabetes are 
due to thickening of walls of alveoli, alveolar capillaries and pulmonary 
arterioles and these changes cause pulmonary dysfunction (4).  
These microvascular complications appear early within 5 to 10 yrs and 
macrovascular complications appear within 15 to 20 yrs from the onset of 
diabetes (6). 
In type I diabetes lung function has been investigated in several clinical 
studies and evidenced reduced lung volume, reduced elastic recoil, diminished 
respiratory muscle performance, decrease in pulmonary diffusion capacity for 
carbon monoxide (7) .  
 As the prevalence of type II DM is increasing, particularly in 
developing countries like India, and since these changes can potentially 
incapacitate the patients, it is of utmost importance to define these changes. It 
is also important to find ways of retarding the progression of disease so that 
they do not become irreversible thus allowing millions of patients to be 
economically productive (2).            
It has been suggested that pulmonary dysfunction may be one of the 
earliest measurable non metabolic alteration in diabetes. So it is important to 
determine whether these lung function changes also occur in type II diabetes.   
Thus, this study was under taken to correlate the lung function in type II 
diabetes with duration of diabetes and to find out whether it is obstructive or 
restrictive pattern. 
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 AIMS & OBJECTIVES 
 
 To study lung function in type II diabetic patients. 
 To correlate pulmonary function test with duration of diabetes mellitus. 
 To find out whether it is obstructive or restrictive. 
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 REVIEW OF LITERATURE 
DIABETES MELLITUS 
 The term diabetes is derived from the greek word meaning ‘siphon’ was 
named by Aretaeus of cappadoica. Cullen added the word ‘mellitus’ meaning 
honey, to the name diabetes (8). 
 Diabetes mellitus is a syndrome characterized by chronic hyperglycemia 
and disturbances of carbohydrate, fat and protein metabolism associated with 
absolute or relative deficiencies in insulin secretion or insulin action. 
   The characteristic symptoms of diabetes mellitus are polyphagia, 
polydipsia, polyuria and weight loss (6). 
 HISTORY: 
  Diabetes was described more than 2000 years ago. Polyuric states, 
clinically resembling diabetes mellitus were described as early as 1550 B.C, by 
Georg Ebers (6). 
 The sugar in diabetic urine was identified as glucose by Chevreul in 
1815. In the 1840’s , Bernard showed that glucose was normally present in 
blood and showed that it was stored in the liver as glycogen for secretion into 
the blood stream during fasting. 
  In 1889, Minkowski and von Mering reported that pancreatectomy 
causes severe diabetes in the dog. In 1893, Laguesse suggested that the 
pancreatic ‘islets’ described by Langerhans in 1869 produced as internal 
secretion that regulated glucose metabolism.
 Insulin was discovered in 1921 by Banting, Best
acid – ethanol extracts of pancreas. 
awarded the noble prize in 1923 and 
Insulin was first used for treatment in J
 INSULIN: 
 Insulin is a polypeptide containing 2 
disulfide bridges, secreted by beta cells of pancreas. 
Figure 1: 
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   In humans, the gene encoding preproinsulin, the precursor of insulin, is 
located on the short arm of chromosome 11. It is 1355 base pairs in length and 
its coding region consists of three exons. The first encodes the signal peptide at 
the N – terminus of preproinsulin, the second the B chain and part of C peptide 
and the third the rest of the C peptide and the A chain. 
 Preproinsulin, an 11.5 KDa polypeptide is rapidly discharged into the 
rough endoplasmic reticulum where proteolytic enzymes immediately cleave 
the signal peptide, generating proinsulin. 
 Proinsulin is a 9-KDa peptide, containing the A and B chains of insulin 
joined by the C peptide. It is transported in micro vesicles to the golgi 
apparatus where it is packaged into membrane – bound vesicles known as 
secretory granules. It is converted into insulin by two endopeptidases.  
 Insulin and C peptide are stored together in the secretary granules and 
are ultimately released in equimolar amounts by a process of regulated 
exocytosis (9). 
Mechanism of action of insulin:    
 Insulin exerts a broad spectrum of anabolic effects on multiple tissues. 
The regulation of whole body fuel homeostasis primarily involves insulin 
action in skeletal muscle, adipose tissue and liver. In these organs, insulin 
promotes uptake and storage of carbohydrates, fat and amino acids. It also 
antagonizes the catabolism of these fuel reserves. Therefore, it is appropriately 
called the “Hormone of abundance”. 
  Insulin receptor is a tetramer made up of two α and two β glycogen 
subunits. All these are synthesized on a single mRNA and then proteolytically 
separated and bound to each other by disulfide bonds. The subunits bind insulin 
and are extracellular, whereas the β subunit span the membrane and the 
intracellular portion have tyrosine kinase activity. 
 Binding of insulin with α subunit of insulin receptor triggers the tyrosine 
kinase activity of the β subunits, producing autophosphorylation of the β 
subunits on tyrosine residues. This autophosphorylation of insulin receptor is 
essential for insulin to exert its metabolic effects. In the tissue insulin increases 
the number of glucose transporters in the cell membrane (GLUT) (10). 
 The primary function of insulin is to lower the plasma glucose 
concentration by increasing glucose entry into the cell and stimulates its 
oxidation and also promotes its storage. At the same time insulin inhibits 
glucose production.  
 In skeletal muscle, insulin stimulates glucose transport and glucose 
storage as glycogen, as well as glycolysis and tricarboxylic acid cycle activity. 
Insulin also lowers hepatic glucose output by inhibiting glycogenolysis, 
gluconeogenesis and augments glycogen formation.  
 Insulin is the only anti-ketogenic hormone. Insulin increases storage of 
fat and decreases the level of free fatty acids and ketoacids in the plasma. 
Insulin is an anabolic hormone, promotes protein synthesis and inhibits 
proteolysis (10).  
  Insulin also enhances cell growth, differentiation and survival as a 
consequence of mitogenic and anti-apoptotic process. Thus oxidative stress, 
endoplasmic reticulum stress and inflammation are associated with insulin 
resistance, obesity and metabolic syndrome (9). 
DIABETES MELLITUS 
 The constellation of abnormalities caused by insulin deficiency is called 
diabetes mellitus. It is characterized by polyuria, polydipsia, polyphagia, 
hyperglycemia, glycosuria, ketosis, acidosis, and coma.  
 The fundamental changes are  
• Decrease in the entry of glucose into peripheral tissues.  
• Increased synthesis of glucose by the liver.   
Therefore there is an excess extracellular glucose and in many cells an 
intracellular glucose deficiency-a situation called “starvation in the midst of 
plenty” (10). 
Based on the pathogenesis responsible for hyperglycemia, diabetes mellitus is 
classified as  
1.  Type I Diabetes Mellitus. 
2.  Type II Diabetes Mellitus. 
3.  Other specific types [Maturity-Onset Diabetes of the Young 
(MODY), due to endocrine disorder, infection ] 
4.  Gestational diabetes. 
 TYPE I DIABETES MELLITUS: 
 It is characterized by the development of a state of complete insulin 
deficiency, as a result of cellular mediated autoimmune destructive process 
which ultimately destroys the β cells.  
TYPE II DIABETES MELLITUS: 
 It represents a heterogeneous constellation of disease syndromes, all 
leading to a final common pathway of hyperglycemia. It is due to impaired 
insulin secretion, insulin resistance and increased hepatic glucose production. 
OTHER SPECIFIC TYPE: 
  1. Defects in insulin secretion are the Maturity-Onset Diabetes of the 
Young (MODY) family, which are a group of autoimmune – dominant 
inherited disorder where there is hyperglycemia at an early age, generally of a 
mild nature. 
  2. Diseases of the exocrine pancreas often cause diabetes through 
destruction of islets – eg: Pancreatitis, Hemochromatosis, Cystic fibrosis. 
  3. Several endocrinopathies are associated with diabetes – cushing 
syndrome, acromegaly, pheochromocytoma, hyperthyroidism and 
glucagonoma. 
 4. Infections are also associated with the development of diabetes – 
mumps, congenital rubella, coxsackie B virus and cytomegalovirus. 
 GESTATIONAL DIABETES: 
  Gestational diabetes is hyperglycemia first detected during pregnancy. 
Screening for GDM is generally undertaken at around 28 wks (3). 
 Of these, type II DM is a predominant form of diabetes worldwide. The 
complications of type II DM are due to microangiopathy and macroangiopathy, 
which affect the eyes, kidneys, nerves, heart and major blood vessels (11). 
WHO – recommended criteria for the diagnosis of diabetes and 
intermediate hyperglycemia 
TEST NORMOGLYCEMIA IFG (mg/dl) IGT (mg/dl) DIABETES 
Fasting plasma 
glucose 
< 100 100-125  ≥126mg / dl 
2 hr plasma 
glucose 
< 140  149 -199 ≥200mg / dl 
Causal plasma 
glucose 
   ≥200mg/ dl     
& 
symptoms 
of diabetes 
 
TYPE II DIABETES MELLITUS 
 Diabetes is renowned as a “silent epidemic” due to the slow progression 
and lack of symptoms in the early stages of disease preclude seeking medical 
attention and preventive care. (9)   
  An epidemic of type II diabetes is underway in both developed and 
developing countries like India due to change in life style, junk foods, 
sedentary life, environmental factors and stressful life . 
MAJOR RISK FACTORS FOR TYPE II DIABETES MELLITUS: 
• Over weight (Body Mass Index ≥ 25 kg / m2). 
• Physical inactivity. 
• Race / ethnicity. 
• Previously identified Impaired Fasting Glucose or Impaired 
Glucose Tolerance. 
• Hypertension (Blood pressure ≥ 140 /90 mm Hg). 
• Triglyceride ≥ 250 mg / dl or HDL cholesterol ≤ 35 mg / dl.  
• History of Gestational Diabetes Mellitus or delivery of a 
baby weighing > 4.1 kg. 
• Poly cystic ovarian disease (11).  
The three major metabolic abnormalities that coexist in type II diabetes are  
1.  Increased hepatic glucose production. 
2.  Target tissues are insulin resistant ( skeletal muscle) 
3.  Abnormal islet cell function. 
 These metabolic abnormalities depend on the genetic, pathologic and 
environmental factors. 
 
 Genetic factors: 
  Type II diabetes is not simply the result of a single gene defect. The 
disease appears to be a polygenic disorder, meaning that different combinations 
of gene polymorphisms may exist among patients. Individuals may be 
predisposed to develop type II diabetes through their inheritance of particular 
combination of genes, but acquired environmental factors are necessary to 
bring out the phenotypic manifestation of hyperglycemia. 
Acquired factors: 
1. Westernized life style is associated with change to a diet that has a 
higher content of total calories, fats, and refined carbohydrates.  
2. The reduced level of physical activity and obesity leads to develop 
diabetes. 
3. Low birth weight is one of the risk factor for the development of 
insulin resistance. 
4. Decline in insulin secretion and insulin sensitivity, results in 
decreased glucose tolerance in aged individuals. 
Pathophysiology of type II diabetes mellitus: 
1. Abnormal beta cell function: 
 The beta cell mass is decreased, due to accelerated β cell apoptosis and 
failure of islet neogenesis and β cell replication to compensate for this loss. 
Glucotoxicity and Lipotoxicity play a major role in impaired β cell function. 
  Glucose stimulated insulin secretion involves transport of glucose into 
cells by a specific glucose transporter termed GLUT2. Genetic deletion of 
GLUT2 leads to loss of glucose stimulated insulin secretion. 
2. Peripheral insulin resistance: 
 Insulin resistance is a metabolic state where there is normal insulin 
production but less biological response. 
 One of the most important effects of insulin was stimulation of glucose 
uptake into skeletal muscle, adipocytes and heart muscle. Tissue glucose 
uptake is mediated by a family of at least five facilitative glucose transporters. 
Out of them, GLUT4 was uniquely expressed in skeletal muscle, adipocytes 
and heart muscle. Upon insulin stimulation, GLUT4 are translocated from the 
intracellular vesicular pool to the plasma membrane, where they begin to 
transport glucose into cell. 
The major manifestation of insulin resistance is decreased glucose disposal. 
The cause for this may be due to  
• Decrease in cellular insulin receptors. 
• Abnormal coupling between the glucose transporters and insulin 
receptors.  
• Decrease in the activity of the glucose transporters. 
• Intracellular defects in various pathways of glucose metabolism (9). 
 
 Mechanism of hyperglycemia induced damage: 
 Due to generalized hyperglycemia, certain types of cells are potentially 
damaged. Because these cells fails to down regulate the glucose uptake, even 
when the extracellular glucose concentrations are elevated.  
 The major target for hyperglycemic damage are vascular endothelial 
cells, which shows no significant change in glucose transport even when the 
glucose concentration is elevated, resulting in intracellular hyperglycemia. 
  1. Hyperglycemia increases glucose metabolism by sorbital 
pathway. This leads to cellular dysfunction, as a result of increase in cellular 
osmolarity, altered redox potential, generation of reactive oxygen species. 
 2. Increased intracellular advanced glycation end products, formed by 
reaction of glucose and other glycating compounds with proteins and to some 
extent, nucleic acids.  
   3. Increase in the expression of Advanced Glycated End products 
receptor and its activating ligand. 
  4. Increase in the formation of diacylglycerol, which activates protein 
kinase C and alters the transcription of genes for type IV collagen, fibronectin, 
contractile proteins and extracellular matrix proteins in endothelial cells and 
neurons. 
  5. Increased hexosamine pathway flux which generates fructose -6-
phosphate, a substrate for O – linked glycosylation and proteoglycan 
production. 
  Finally a single process due to increased mitochondrial production of 
oxygen free radicals activates each of this mechanism.  
 The consequence of persistent hyperglycemia is increased superoxide 
production which explains the continuing progression of tissue damage even 
after the improvement of glycemic levels (glycemic memory). So early 
glycemic control appears to be important in order to reduce vascular 
complications in subsequent decades (9). 
Biochemical test to be done to diagnose and monitor the efficacy of   
treatment to DM: 
 Glycated hemoglobin and blood glucose are the two most frequently 
used measure of glycemia in current practice. 
 1. Fasting blood glucose should be obtained after an approximately 10 
hr fast. Urine glucose measurement is not used in diabetic diagnosis; however 
some patients use this measurement for monitoring purposes. 
 In an asymptomatic patient, if fasting blood glucose is 126 mg/dl or 
above on more than one occasion, the diagnosis of DM is confirmed. 
 
 
 2. Oral glucose tolerance test: 
 Patient should be on a normal to high carbohydrate intake for 3 days 
before the test. The patient should be fasting for at least 10 hrs and not more 
than 16 hrs. The test should be performed in the morning because of the 
hormonal diurnal effect on glucose. 
 Fasting blood sample is collected. A solution containing 75gm of 
glucose is given orally and blood for plasma glucose measurement is drawn 
2hrs later. If the two hr glucose is 149 -199 mg/dl is called impaired glucose 
tolerance and > 200 mg/dl is called diabetes.  
 3. Glycosylated hemoglobin is the most reliable method to monitor 
long term diabetes control rather than random blood glucose. HbA1c is the 
most commonly detected hemoglobin, is a glucose molecule attached to one or 
both N- terminal valine of the β- polypeptide chain of normal adult 
hemoglobin(9) . 
  HbA1c levels serve as a retrospective indicator of the average glucose 
concentration over the previous 6-8 wks, as the average life span of red blood 
cell is about 120 days. The rate of formation is directly proportional to the 
plasma glucose concentration. The levels of HbA1c are directly related to the 
risk of developing diabetic complications (9). 
 
 
  
 
 
 
 
 
 
 
 
Complications of diabetes mellitus: 
1. Acute complications: 
• Metabolic – diabetic ketoacidosis. 
             Hyperglycemic hyperosmolar syndrome. 
             Hypoglycemia. 
• Others – acute infections. 
Acute coronary syndromes. 
Cerebrovascular accidents. 
2. Chronic complications: 
• Microvascular – Neuropathy and Retinopathy. 
• Macrovascular – Hypertension, Coronary arterial disease. 
 
HbA1c 
Mean plasma glucose 
mmol/L mg/dl 
6 7.0 126 
7 8.6 154 
8 10.2 183 
9 11.8 212 
10 13.4 240 
11 14.9 269 
12 16.5 298 
 • Others – Diabetic foot, Gastro intestinal and genitourinary 
dysfunction. 
• Dermatological disorders. 
• Infections. 
Management of Type II Diabetes: 
 The management of type II diabetes mellitus was very important to 
achieve good glycemic control, in order to prevent or reduce the severity of 
chronic complications. 
1. Lifestyle intervention. 
 Diet –the caloric content of the diet is based on the patient’s current 
weight. 150 kJ / kg for men and 140 kJ/kg for women are reasonable initial 
values in most patients. 
 The protein requirement for good nutrition is about 1.0 to 1.5 g/kg of 
body weight/ day. The average fat intake should be 30 % of total calories and 
the remaining calories are assigned to carbohydrate. Increasing the fiber 
content of the diet is helpful. 
 Not only the amount of carbohydrate, but also the quality of 
carbohydrate is important for individuals with diabetes. The amount of 
carbohydrate is an essential factor for post-prandial glucose results in people 
with type I DM and type II DM. In the process of achieving desirable glycemic 
control, many individuals use either carbohydrate counting, carbohydrate 
 exchanges or experience – based estimation of consumption of carbohydrate at 
meals or snacks.  
 The glycemic index (GI) of a carbohydrate – containing food describes 
its post prandial glucose response over 2hrs in the area under the good glucose 
curve compared with a reference food with the same amount of carbohydrate, 
usually 50 g glucose. Foods can be differentiated into high (GI: 70-100) 
average (GI: 55-70) or low (GI:  55) glycemic index food. 
 High GI foods (e.g.: mashed potatoes, sugary drinks, cookies) should be 
substituted with low GI foods (e.g. oats, whole grain breads, certain raw fruits) 
as they lower post-prandial hyperglycemia (9). 
 Exercise: One of the important lifestyle modifications in diabetes is 
exercise. It is associated with improved glycemic control, insulin sensitivity, 
and cardiovascular fitness and remodeling. 
 Self-monitoring of blood glucose is an integral part of the process, 
allows the patients to assess the effect of their lifestyle and pharmacologic 
efforts in controlling post prandial glucose levels (3). 
2. Pharmacotherapy. 
The available oral hypoglycemic agents are 
• Bigunaide Metformin which counters insulin resistance and decreases 
blood glucose by reducing hepatic glucose production and also increases 
the glucose uptake by the liver. 
 • Sulfonylureas (eg: gliclazide, glimepride) act on the pancreas β cells to 
stimulate insulin secretion. 
• Meglitinides, also known as prandial insulin releasers, taken before 
meals to boost insulin levels during digestion, thereby reducing prandial 
hyperglycemia. 
• Thiazolidinediones alter the expansion of certain insulin sensitive genes 
by stimulating the peroxisome-proliferator-activated receptor γ and 
produce a slow –onset-glucose lowering effect, attributed mainly to 
increased insulin sensitivity.  
• α – glucosidase inhibitor (eg: acarbose) show the digestion of 
carbohydrates by competitive inhibition of intestinal α – glucosidase 
enzymes. 
The advanced stages of type II diabetes insulin therapy should be initiated, 
along with oral hypoglycemic agents (9). 
RESPIRATORY SYSTEM 
 The organ that supports gas exchange comprises the respiratory system. 
They are the upper airways, lower airways, lung parenchyma, chest wall, 
respiratory muscle, pulmonary blood vessels, support nerves and lymphatics.
Lung is a sophisticated conglomerate of alveolar air sacs, whose primary 
function is continuous absorption of O2 and excretion of CO2 (12). 
  Lungs are multilobed, cone shaped, sponge like organs that lie within 
the pleural cavities bounded by chest wall & diaphragm. The average adult 
 lungs are low – density organs that occupy a volume of approximately 3.5 liters 
and weight approx 900gm. 
 The chest wall and the lungs are elastic structures that can expand and 
recoil when inflated with air. This elasticity results from surface tension forces 
in the alveoli & from the elastic properties of the tissues & various connective 
tissue fibers. The presence of elastin fibers in the alveolar walls, the small 
airways and pulmonary capillaries produces elastic recoil. 
 Collagen and reticulin fibers located in the visceral pleurae and airway 
walls combine to create a basket like helical network of connective tissue fibers 
around the alveoli and airway walls that extends to the lumen. 
 Tendency of the lung to collapse is counteracted by the thoracic walls 
tendency to spring outward and to hold the lung inflated. The tension 
developed by these two opposing tendencies result in the development of 
subatmospheric intrapleural pressure (13). 
INSPIRATION AND EXPIRATION: 
 Inspiration is an active process. The muscles of inspiration are 
diaphragm, external intercostals, sternocleidomastoid muscle, serratus anterior 
and scalene muscle. Their contraction increases the lung volume. 
 During inspiration the intrapleural pressure becomes more negative i.e. 
from -2.5 mm Hg to -6 mm Hg due to expansion of the chest wall. This pulls 
 the surface of lungs with greater force creating negative intrapulmonary 
pressure. 
 At the end of inspiration, the inspiratory muscles relax and the recoiling 
force of the lungs begins to pull the chest wall back to expiratory position. The 
pressure in the airway becomes slightly positive, and the air flows out of the 
lungs. 
 Expiration during quiet breathing is passive. At the end-expiratory 
position where the recoil force of the lungs and recoil force of thoracic cage 
balance, the pleural pressure returns back to -2.5 mm Hg (10). 
RESPIRATORY UNIT: 
 It is composed of a respiratory bronchiole, alveolar ducts and alveoli. 
There are about 300 million alveoli in the lungs; each alveolus is about 0.2 mm 
in diameter. The alveolar walls are thin and has solid network of 
interconnecting capillaries. Gas exchange occurs between the alveoli and 
pulmonary capillary blood. 
 RESPIRATORY MEMBRANE: 
The layers of the respiratory membrane are 
1. A fluid layer containing surfactant. 
2. A layer of alveolar epithelium. 
3. The epithelial basement membrane layer. 
 4. A thin interstitial space between the alveolar epithelium & the 
capillary membrane. 
5. A capillary basement membrane. 
6. The capillary endothelial cell layer. 
 Despite the large number of layers, the thickness of the respiratory 
membrane is 0.2 µm and the total surface area is about 70 square meters (14). 
PULMONARY FUNCTION TEST 
 The pulmonary function tests are very important age old test to assess 
the respiratory function of a person. They are important for clinical, diagnostic 
and prognostic values (7). 
 The factors that determine the lung functions at a particular point in 
adult life are  
1. The maximally attained level of lung function. 
2. The onset of decline of lung function. 
3. The rate of decline of lung function. 
 Normally the maximum lung function is around the ages of 20 and 25 
years. After the age of 30-35 years there is decline in lung function (15). 
 It has been observed that the lung function have been mild to moderately 
reduced before they are appreciated by the patient or clinical signs are 
observed.  
  Therefore, the subjective assessment of the severity of the disease is 
sometimes difficult. It may lead to inadequate treatment interventions and 
control of the disease.  
 Measurements of the lung function tests are important in diagnosis and 
monitoring of treatment of lung disorders (16). 
The ability of the lungs to perform gas exchange depends upon 
1. The diaphragm and thoracic muscles which are capable of expanding 
the thorax and lungs to produce a subatmospheric pressure. 
2. The airways must be unobstructed so that it allows gas flow into the 
lungs and reach the alveoli. 
3. The cardiovascular system must circulate blood through the lungs 
and ventilated alveoli. 
4. O2 and CO2 must be able to diffuse through the alveolar – capillary 
membrane. 
  Pulmonary function tests can provide valuable information about 
these important individual processes that support gas exchange i.e. ventilation, 
diffusion & perfusion (13). 
 
 Pulmonary function tests can be divided into categories based on the 
aspect of lung function they measure 
1) Airway function 
2) Lung volume and ventilation 
 3) Diffusion capacity tests. 
4) Blood gases and gas exchange tests. 
5) Cardiopulmonary exercise tests. 
6) Metabolic measurements. 
Airway function and lung volumes are almost always measured with 
spirometry. 
SPIROMETRY 
 Spirometry is a powerful tool that can be used to detect, differentiate, 
follow and also to manage patients with pulmonary disorders. It typically 
assesses the lung volumes and flows. It is also useful to determine the patterns 
of lung dysfunction (4). 
 In the middle of 18th century, Hutchinson developed a simple water 
sealed spirometer that allowed measurement of vital capacity. He also observed 
that VC was related to the standing height of the patient (17). 
 In 1679, Borelli first measured the volume of air inhaled by single deep 
breath. The need for temperature correlation was pointed out by Goodwyn 
(1788). In 1831, Thackrah showed the volume of air to be less in women than 
in men. 
 Davy (1800) measured the residual volume by gas dilution method. 
DuBois and colleagues (1956) developed a method called whole body 
plethysmography (17). 
  Forced vital capacity is a refinement of the simple VC test. During the 
1930s, Barach observed that patients with asthma exhaled more slowly than 
healthy patients. He noted that airflow out of the lungs was important in 
detecting obstruction of the airways. He also used kymograph to display VC 
changes as a spirogram. 
 In 1950, Gaensler began using a microswitch in conjuction with water 
– sealed spirometer to time FVC. He observed that healthy patients consistently 
exhaled approximately 80% of their FVC in 1 second and almost all of the 
FVC in 3 seconds. He used the FEV1 to assess airway obstruction. 
 In 1955, Leuallen and Fowler demonstrated a graphic method to assess 
airflow. They measured airflow between the 25% and 75% points on a forced 
expiratory spirogram. This was described as maximal mid expiratory flow rate 
[MMFR] and now referred to as Forced Expiratory Flow 25% - 75%. 
  In the late 1950s, Hyatt and others began using the flow – volume 
display to assess airway function. The tracing was termed the Maximal 
Expiratory Flow Volume (MEFV) curve. By combining it with an inspiratory 
maneuver, a closed loop was displayed called the flow – volume loop. 
 In the 1960s, Wright used the peak flow to monitor asthmatic patients. 
Peak Expiratory Flow (PEF) is measured using either a flow – sensing 
spirometer or a peak flow meter. 
 Maximal Voluntary Ventilation (MVV) was described as early as 
1941. Cournand and Richards originally called it the maximal breathing 
 capacity. The MVV gives an estimate of the peak ventilation available to meet 
physiologic demands (17). 
 Nowadays, modern computerized pulmonary function systems allow 
very sophisticated data handling and storage, graphic display of maneuvers, 
accurate calculations and enhanced reporting capabilities. They combine 
physical transducers, analog to digital converters, and computer software to 
process and record physiologic data. Microprocessor-based spirometers are 
now small enough to be handheld and portable (17). 
TYPES OF SPIROMETERS: 
Broadly there are two types of spirometers: 
  I.VOLUME DISPLACEMENT SPIROMETERS: 
These records the amount of air exhaled or inhaled within a certain time.  
These widely used types of volume spirometer are  
1) Water seal spirometer. 
2) Dry rolling seal spirometer. 
3) Bellows spirometer.  
  II. FLOW SENSING SPIROMETER OR PNEUMOTACHOMETER: 
 These measures how fast the air flows in or out as the volume of air 
inhaled or exhaled increases.  
 
 The most common types of flow spirometers are 
1) Rotating vanes (Turbines) 
2) Pressure differential flow sensing spirometers. 
3) Hot wire anemometers. 
4) Pitot tube flow sensing spirometers (16). 
 Spirometry can be performed in either the sitting or standing position for 
adults and children. The use of nose clips is recommended for spirometric 
measurements that require rebreathing, even if just for a few breaths. 
American Thoracic Society Standards for Spirometry are   
 The spirometer should be able to measure up to 30 seconds, while 
measuring the slow vital capacity and for FVC, the time capacity should be at 
least 15 seconds. 
 It should have a capacity of at least 8 Liters and should measure volumes 
with less than 3% error or within 50ml of a reference value, whichever greater. 
 A diagnostic spirometer should measure flow of about 95% accurate over 
the entire 0 to 14 L/sec range of gas flow. 
 The values produced by spirometer is corrected for body temperature, 
ambient pressure, and saturated with water vapour (BTPS). 
 The standards include verifying volume accuracy with a 3 liter 
calibration syringe at least daily (13). 
 INDICATIONS OF SPIROMETRY: 
1. To detect the presence or absence of lung disease. 
2. To monitor the progress of the disease. 
3. To monitor the efficiency of treatment. 
4. To evaluate the respiratory fitness prior to surgery. 
5. To measure effects of occupational or environmental 
exposure 
6. To evaluate disability or impairment (17). 
CONTRAINDICATIONS OF SPIROMETRY: 
1. Hemoptysis of unknown origin. 
2. Respiratory infections. 
3. Pneumothorax. 
4. Recent myocardial infarction or pulmonary embolus. 
5. Recent eye surgery or surgery of thorax or abdomen. 
6. Thoracic, abdominal or cerebral aneurysms (4). 
 
LUNG VOLUMES AND CAPACITIES 
 Lung volume determination usually includes the VC and its subdivisions, 
along with functional residual capacity. From these two basic measurements, 
the remaining lung volumes and capacities can be calculated. The most 
common reason for measuring lung volumes is to identify restrictive lung 
disease. Lung volumes are almost ai
spirometry. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Diagrammatic representation of lung volumes and capacities 
 
 
rways measured in conjunction with 
 
 
based on a simple spirogram. 
 The four lung volumes are  
1. Tidal volume is the volume of air inspired or expired during 
quiet breathing and is about 500ml. 
2. The amount of air inspired with maximum inspiratory effort 
above the normal tidal volume is called inspiratory reserve 
volume: it is about 3000ml. 
3. The expiratory reserve volume is the volume of air expired 
with maximum expiratory effort after the normal tidal 
expiration: this normally amounts to about 1100ml. 
4. The volume of air remaining in the lungs after the forceful 
expiration is known as residual volume: it is normally about 
1200ml. 
The pulmonary capacities are  
1. The maximum amount of air inspired after completing the tidal 
expiration is defined as inspiratory capacity and is about 3500ml.  
2. The functional residual capacity is the amount of air remaining in 
the lung at the end of normal expiration and is about 2300ml. 
3. The vital capacity is the maximum amount of air expired forcefully 
after a maximum inspiratory effort and is about 4600ml.  
4. The total lung capacity is the volume of air present in the lung 
after a maximum inspiration and is about 6 liters (14). 
 
 Indices based on volume: 
  The volume of gas measured from a slow, complete expiration after a 
maximal inspiration, without forced or rapid effort is known as vital capacity. It 
is also referred to as the slow vital capacity, distinguishing it from forced vital 
capacity. 
 Forced vital capacity is defined as the maximum volume of expired 
forcefully and rapidly after a maximal inspiration. 
 In healthy individuals FVC equals VC or FVC & VC should be within 
200ml of each other. Reduced FVC is a non specific finding. Values lower than 
80% of predicted or less than the 95% confidence limit are considered 
abnormal. Low FVC may be caused either by obstruction or restriction. 
 FEV1 is the volume of air expired in the first second of an FVC 
maneuver. It is reported as a volume, although it measure flow over a specific 
interval. The index was pioneered by Tiffeneau and Pinelli and by Gaensler. 
FEV1, like FVC may be reduced in either obstructive or restrictive patterns. 
 FVC is measured concurrent with FEV1 and its main application is to 
standardize FEV1 for lung size using the relationship:  
      FEV1% = (FEV1/FVC) × 100 
The relationship is a component of most lung function reports (12). 
 FEF25 – 75% is the indicative of the status of the medium to small airways. 
It is measured from a segment of the FVC. Typical values for healthy young 
 adults average 4 to 5 L / sec.  It is useful in to detect air flow limitation in the 
early stage itself. 
  PEF primarily measures large airway function. Effort dependence of 
PEF makes it a good indicator of patient effort during spirometry. It is 
particularly useful for monitoring asthma patients at home. 
 Maximal voluntary ventilation (MVV) is the maximum volume of air 
expired in a specific period of time (12 sec for normal subjects).  It tests the 
overall function of the respiratory system. It is influenced by airway resistance, 
respiratory muscle, compliance of the lung/ chest wall and ventilatory control 
mechanisms. Values in healthy young men average between 150 – 200 L/min.                             
 MVV is decreased in patients with moderate or severe obstructive 
disease. MVV may be normal in patients who have restrictive pulmonary 
disease. They can compensate by performing the MVV maneuver with VT and 
breathing rates (17). 
Indices based on time: 
 The time taken to expire a specified portion of the forced vital capacity is 
known as forced expiratory time (FET). A time in excess of 4s is evidence 
for some degree of airflow limitation. Spirogram or volume-time curve, the 
volume of air exhaled is plotted against time. It reports four major test results. 
They are FVC, FEV1, FEV1/FVC % and FEF25 – 75% (18). 
 
Indices from the relationship of flow to volume:
 The flow – volume curve 
flows and lung volume. The curve can be for expiration alone or for expiration 
and inspiration (flow 
proved to be a value for diagnosis. 
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 plotted downward. Peak flows for expiration and inspiration (PEF and PIF) can 
be read directly and the instantaneous flow (FEF) at any point in the FVC also 
can be measured directly (17).  
 The procedure to record the flow-volume loop is to ask the patient to 
perform FVC maneuver, inspiring fully and then exhaling as rapidly as 
possible. To complete the loop, the patient inspires as rapidly as possible from 
the maximal expiratory level back to maximal inspiration. 
 The flow-volume loop gives data for FVC, PEFR and Expiratory flow 
rates. When the expiratory flow-volume curve is divided into quarters, the 
instantaneous flow rate which 50% of the VC remains to be exhaled is called 
the FEF 50%, the instantaneous flow rate which 75% of the VC remains has been 
exhaled is called the FEF75% and the instantaneous flow rate which 25% of the 
VC has been exhaled is called the FEF 25% (18). 
PATTERNS OF ABNORMALITIES IN PFT RESULTS 
The three main types of ventilatory dysfunctions observed in spirometry are 
1. Obstructive lung disorders in which the FEV1 is decreased, the FVC is 
usually normal and the FEV1/ FVC ratio is decreased. Obstructive lung disease 
can be caused by conditions such as asthma, bronchitis, COPD, etc. 
2.  Restrictive lung disorders - the FEV1 and FVC are both decreased, leaving 
a normal FEV1/ FVC. Restrictive lung disease can be caused by conditions 
 such as fibrosis, interstitial lung disease, pneumoconiosis, sarcoidosis, obesity, 
pregnancy and loss of lung tissue due to surgery etc. 
3.  Mixed function disorders - all the three parameters FVC, FEV1 and FEV1/ 
FVC are reduced. Mixed pattern may be seen in conditions such as 
bronchiectasis, cystic fibrosis, post-tubercular fibrosis, allergic 
bronchopulmonary Aspergillosis etc (13). 
 
INTERPRETATION OF SPIROMETRY RESULTS (16) 
 
 
 
 
 
 
 
 
 
 
 
 
FEV1/FVC ratio 
Low Normal 
Obstructive lung 
diseases 
FVC FVC 
Low Normal Low Normal 
Pure obstructive or 
combined obstructive 
and restrictive disease 
Pure obstructive 
lung disease 
Restrictive lung 
disease 
Normal study 
 Pulmonary Function 
Parameter 
Obstructive Type Restrictive Type 
FVC (L) ↓ ↓ 
FEV1 ↓ ↓ 
FEV1/ FVC% ↓ Normal 
FEF25 – 75%  (L/SEC) ↓ Normal to ↑ 
PEFR ↓ Normal 
 
 
Severity of pulmonary impairments based on a percentage (%) of the 
predicted values 
Degree of impairment Obstruction based on 
FEV1 
Restriction or  
Obstruction based on 
TLC,FRC,RV 
Normal 80%-120% 80%-120% 
Mild 70%-79% 70%-79% or 121%-130% 
Moderate 60%-69% 60%-69% or 131%-140% 
Moderately Severe 50%-59% 50%-59% or 141%-150% 
Severe 35%-49% 35%-49% or 151%-165%  
Very Severe 35% 35% or >165% 
 
 
 LUNG FUNCTION IN DIABETES 
 Spirometry is the non-invasive test that quantifies the physiological 
reserves that are not clinically affected by diabetes. 
 The pathogenesis of diabetic complications is due to involvement of both 
microangiopathy and non-enzymatic glycosylation of tissue proteins. This 
results in impaired collagen and elastin cross-linkage, reduction of strength and 
elasticity of connective tissue (5). 
 Since the lung has an abundant connective tissue, it may be a ‘target 
organ’ in diabetic patients (5). Lung function also provides useful measures of 
the progression of systemic microangiopathy in diabetic patients (4).  
 The another important issue is that the lungs have a large surface area 
which has the ability to transfer large amounts of oxygen from the air to blood, 
favours a convenient portal of entry of therapeutic agents (55). 
 It was formerly thought that diabetes did not affect the lungs. However in 
the mid 1980s, the FVC, FEV1, TLC, FRC & RV were observed to be reduced 
in diabetes. There was no evidence of airflow limitation. The finding was 
attributed to a reduction in lung compliance (12). 
The decreased lung function is due to  
1. Glycosylation of proteins such as collagen in the lungs and chest wall. 
2. Decrease in muscle strength (15). 
   The pulmonary pathologic changes such as thickened alveolar epithelial 
and pulmonary capillary basal laminae are secondary to pulmonary 
microangiopathy (20). 
 Long term diabetes mellitus is characterized by widespread alterations of 
basal lamina. The classic morphologic findings in diabetic microangiopathy are 
the thickening of basement membranes in capillaries. This is a generalized 
phenomenon which affects both vascular and nonvascular tissues. Weynand et 
al demonstrated the thickenings of basal lamina of pulmonary capillaries are 
homogenous throughout the whole lung parenchyma (21).  
 All pulmonary function parameters were lower in diabetics of both sexes 
than non diabetic controls with greater reduction in males than in females and 
were due to diminished elastic recoil of lungs (22).  
 The reasons are some genetic factor involved for abnormal collagen 
structure linked to genetic predisposition of diabetes mellitus  or age related 
changes in lung functions which might appear early in diabetic males than 
females (22). 
The effects of diabetes on the respiratory system are numerous. They are 
• Decreased lung volumes. 
• Reduced vital capacity. 
• Reduced TLC. 
• Reduced pulmonary elastic recoil. 
• Impaired pulmonary diffusion. 
 • Decreased inspiratory muscle strength. 
• Increased bronchial responsiveness with increased 
threshold for cough response. 
• More prone to develop respiratory tract infections. 
• Sleep apnea is common in those having autonomic 
neuropathy (19). 
 Diabetes mellitus and lung function have a two way relationship. It is 
important to assess respiratory dysfunction caused by diabetes mellitus. It is 
even more pertinent, in non- diabetic subjects, to assess the risk of diabetes 
mellitus.  
 The impaired lung function may be the forecast quite reliably many years 
before the actual diagnosis of diabetes mellitus (23). 
 Augusto A. Litonjua et al observed that the diabetics had reduced lung 
function (especially FEV1 and FVC but not FEV1 / FVC ratio) than non – 
diabetic subjects. This decreased lung function is found to be present many 
years before the subjects are diagnosed as having diabetes mellitus (15). 
 In a retrospective analysis diabetics were found to have significantly 
lower mean FEV1 and FVC values than for the control group. Diabetes also had 
an effect on the age related changes in lung function (24). 
 Dharwadkar et al observed that all the values of FVC, FEV1, FEV1 / FVC 
% and PEFR are reduced significantly in diabetics when compared with 
healthy controls. They also reported a negative correlation between the 
 respiratory parameters and glycemic status of diabetic patients. The reason for 
this reduced lung function is respiratory muscle weakness (7).       
 Muhammad Irfan et al observed that the diabetic patients had impaired 
lung function independent of smoking. There was a decrease in FVC, FEV1, 
and SVC as compared to their controls. They also reported that respiratory 
muscle endurance was impaired which was determined by MVV test (25). 
 Davis et al conducted a large community-based study in Western 
Australia in type II diabetic patients. They demonstrated that VC, FVC, FEV1 
and PEF were decreased in type II diabetic patients. An increase of 1% in mean 
HbA1C was associated with a decrease of 4% in predicted FVC. They also 
suggested that the chronic complications of type II diabetes are reduced lung 
volumes and air flow limitation (26). 
 Sreeja et al reported that there was a significant decrease in FEV1 / 
FVC% and FEF25 – 75%   in diabetic subjects as compared to controls (27). 
 Yel and associates  observed in their cross- sectional study that middle – 
aged type II diabetics had significantly lower FEV1, FVC, FEV1 % predicted 
and FVC% predicted compared with non diabetics (28). 
 Diabetics with inadequate glucose control had reduced lung function than 
those with adequate control and the impairment is more consistent with a 
restrictive lung disorder (29).   
  McKeever et al demonstrated that in adults without diabetes, but 
impaired glucose regulation as indicated by glucose tolerance testing, higher 
levels of glycosylated hemoglobin, plasma insulin and C peptide are associated 
with impaired lung function in a dose – response manner (30). 
 O.L.Klein et al conducted a retrospective study and observed that FEV1 
and FVC were significantly reduced in patients with diabetes than those 
without diabetes (31). 
 Banu S et al, found that Mean Expiratory Pressure (MEP) was 
significantly reduced which was due to respiratory muscle weakness (32). 
 P.Lange et al in their longitudinal study in diabetic and non diabetic 
adult’s participants of the Copenhagen City Heart study found that FEV1 and 
FVC were significantly lower in diabetic subjects when compared with healthy 
individuals with an average reduction of nearly 8% of the predicted value (33). 
 
LUNG FUNCTION AND DURATION OF DIABETES 
 There is a definite correlation between the duration of diabetes 
mellitus and the tissue abnormalities. As the duration of diabetes increases, 
there is an increase in thickening of capillary basement membrane, capillary 
permeability, blood flow and viscosity and decrease in platelet function. These 
changes were observed in diabetics, particularly in the ones who are genetically 
susceptible.  
  As a result of these alterations, there are chances for the formation of 
microthrombi and ischemic tissue damage (34). 
 The duration of diabetes was a significant determinant of FEV1 and a 
trend was seen for the FVC. The underlying mechanism of reduced pulmonary 
function in diabetes was due to inflammation which leads to progressive 
decrease in lung function and the severity of which would increase with 
duration of diabetes (35). 
 Mori showed that DLCO% decreased significantly as the duration of DM 
increased and the reduction was greater in patients with diabetic 
microangiopathy and in type I diabetes mellitus (36). 
  In a cross sectional study the diabetic population were found to have 
abnormal pulmonary function, viz, mild reduction of lung elastic recoil and a 
reduction in pulmonary diffusing capacity because of a reduced pulmonary 
capillary blood volume which was correlated with duration of diabetes 
mellitus(37). 
 Timothy et al observed that duration of diabetes was an independent 
predictive of reduced lung function whereas HbA1C was not (38). Kanya kumara 
DH et al found that as the duration of diabetes increases, the restrictive profile 
becomes more prominent (39). 
 
 
 PATTERN OF LUNG DISEASE IN DIABETES 
 The most abundant protein in the human lung is collagen, which is 
important in defining lung structure and function. This collagen network 
confers strength to the structure and is dependent on cross-linkage between 
collagen and elastin. This is most important in conferring elasticity to the lung. 
However, increased collagen cross – link may increase lung stiffness. 
  The plausible mechanisms for restrictive respiratory defect are increased 
elastic recoil, decreased chest wall compliance and muscular weakness (40). 
 The markers of inflammation are Interlukein-1, Interlukein-6, and tumor 
necrosis factor. These are associated with insulin resistance and this has been 
demonstrated in recent epidemiologic studies. 
 In another study by Arnalich et al, found that the inflammatory markers 
are reduced with the treatment of diabetes, suggesting that diabetes may be a 
cause of systemic inflammation. This is due to the proinflammatory effects of 
advanced glycation end-products. 
 Walter, Beiser, Givelber, et al demonstrated relationship between 
glycemic state and reduced lung function. They also observed a slightly 
increased FEV1 / FVC ratio suggesting a restrictive pattern of respiratory 
impairment (10). 
   Nakajima et al observed a restrictive pattern of pulmonary function but 
not obstructive pattern due to decrease in FVC and normal FEV1/FVC ratio. 
 This was due to metabolic disorders and metabolic syndrome in a severity 
dependant manner (41). 
 Sanjeev Verma et al reported a significant reduction in mean FVC and 
mean FEV1 but no significant change was observed in FEV1 / FVC ratio, 
PEFR, FEF25 – 75%. They concluded that there was a restrictive type of 
respiratory function in diabetic patients (2). 
 Meo et al observed that there was a drop of FVC, FEV1, FEF25 – 75%   and 
PEF parameters suggests that type II diabetes adversely affect the lung 
function. This impairment shows a restrictive pattern of airways disease and is 
associated with dose-effect response of period of exposure to disease (23). 
 Nandhini et al also reported that there was a predominant restrictive 
pattern of the disease in type II diabetes mellitus, with a significant reduction of 
FVC and normal FEV1 / FVC % (42). 
 The pattern of abnormal pulmonary function observed in Boulbou et al 
study, low TLC, DLco and preserved FEV1 / FVC % was suggestive of a 
restrictive type of lung disease. The possibility exists that the reduced TLC was 
due to the result of increased chest wall stiffness, but it seems that the alteration 
of lung connective tissue at a biochemical level was responsible for the 
development of abnormal lung mechanics (43). 
  In a morbid obese woman, Diabetes is a risk factor for respiratory 
function impairment. In Lecube et al study, detected that inadequate control of 
diabetes was associated with an obstructive pattern of pulmonary 
 abnormalities. It is possible that type II diabetic patient’s exhale less air from 
the lungs at a slower rate than non-diabetic individuals, so there was an 
increase in residual volume (44). 
In a prospective study of middle-aged men and women without known 
lung disease, lower vital capacity predicted and the subsequent development of 
type II diabetes. The possible explanation are hypoxia induced insulin 
resistance, adverse fetal or early- life conditions through long-standing altered 
gene expression, inflammatory precursors and decreased muscle strength (45). 
Chance and associates observed in their study that alveolar 
microvascular reserves were reduced in type II diabetes, reflecting restriction of 
lung volume, alveolar perfusion and capillary recruitment. This reduction 
correlates with glycemic control and is aggravated by obesity (46). 
 Wannamethee and Associates in a large prospective study observed 
that restrictive lung function is associated with the development of type II 
diabetes. This association was due to inflammatory pathways (47). 
Role of breathing exercise: 
 Regular breathing exercises are important to improve the lung function 
in diabetics. The exercises to improve the respiratory muscle strength are  
1) Walking or bicycling that improves overall conditioning. 
 2) Breathing control techniques such as pursed lip breathing, diaphragmatic 
breathing improves ventilation, decreases air trapping, decreases work 
of breathing and improves breathing patterns. 
3) Respiratory muscle training using resistive respiratory loading may 
strengthen both the inspiratory and expiratory muscles (13). 
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 MATERIALS AND METHODS 
  40 healthy volunteers were randomly recruited from the general 
population residing around Thanjavur Medical College. 40 type II diabetic 
patients were selected from the diabetic outpatient department of age group 35 
– 55yrs with duration of diabetes more than 2 yrs. This was a case-control type 
of study done in the period may 2011-2012. 
The study group was divided into two groups based on the duration of diabetes 
as 2-5yrs and 6-10yrs. 
Group I - 40 healthy controls. 
Group II - type II diabetic patients having diabetes for 2-5 years. 
Group III - type II diabetic patients having diabetes for 6-10 years. 
  An informed written consent was obtained from all the participants 
prior to their participation in the study. The study protocol was approved by the 
Institutional ethical committee of Thanjavur Medical College. 
 Anthropometric measurements like height, weight were measured and 
BMI was calculated. Glycemic status for the participants was measured by 
doing fasting & post prandial blood sugar. HbA1c was determined by 
turbidimetric immunoassay and its value less than 7 % was taken for study. 
Detailed history and thorough clinical examination was carried out. 
 
 Inclusion criteria: 
 Apparently healthy individuals with type II diabetic patients on oral 
hypoglycemic drugs and having diabetes for more than 2 years duration of age 
group 35 – 55years. Thorough clinical examination and history was obtained 
from the subjects in order to determine the health status of the individual. 
Exclusion criteria: 
• Smokers. 
• Patients with history of cardiac/respiratory disease (hypertension, 
myocardial infarction, bronchial asthma, bronchitis, tuberculosis). 
• History of recent surgery.  
• History of recent respiratory tract infection. 
• History of occupational exposure. 
 Pulmonary function tests were done using computerized spirometer 
which was standardized according to American Thoracic Society performance 
criteria [Spiro Excel – Digital Spirometer – Medicaid systems].   
 The pulmonary function parameters like forced vital capacity [FVC], 
FEV1, FVC/FEV1%, PEFR, slow vital capacity [SVC] and maximum voluntary 
ventilation [MVV] are recorded. The Pulmonary function test was performed 3 
times on the same day in sitting posture with two minutes interval and the best 
of the three was taken. 
 
    Blood samples were drawn for estimation of fasting blood sugar 
and glycated hemoglobin after 6 hours of fasting. The subject was asked to take 
breakfast and post-prandial blood sugar was also checked after 2 hours. 
 The pulmonary function data are represented in three columns. These 
columns show the predicted values, measured values obtained during testing 
and the percent of predicted values for each test. A common method of 
comparison is to compute a percentage of the predicted value. 
PRECAUTIONS: 
i. The subject must be comfortable and relaxed. 
ii. The apparatus should be sterilized and cleaned properly. 
iii. The subject should sit with his spine erect and nostril closed.  
iv. The mouth piece is placed in the subject’s mouth in such a way 
that the mouth piece remains fitted between the teeth and the lips. 
v. The subject should be demonstrated and trained about the different 
maneuver. 
vi. Minimum three recordings should be taken for each maneuver at a 
gap of two minutes each and the best of the three should be taken. 
PROCEDURE: 
Forced vital capacity: 
 The subject is asked to breathe out forcefully with a maximum effort 
possible after taking a deep inspiration and this is followed by a forced 
 inspiration to produce a complete image of forced breathing called a flow – 
volume loop. 
Criteria for acceptability: 
1. Maximal effort; No cough or glottis closure during the first second; no 
leaks or obstruction of mouth piece. 
2. Good start- of- test ; extrapolated volume < 5% of FVC or 150ml 
3. Duration-6 seconds of exhalation. 
4. Three acceptable spirograms are obtained; two largest FVC values 
within 200ml and two largest FEV1 values within 200ml are taken. 
Slow vital capacity: 
 The subject is instructed to inhale and exhale normally to record the 
tidal volume. Then the subject is asked to breathe in as much as possible after 
the normal expiration and exhale maximally to record inspiratory and 
expiratory volume. 
Criteria for acceptability: 
1. Two acceptable VC maneuvers should be obtained and volumes within 
200ml 
2. VC should be within 200ml of FVC value. 
Maximum voluntary ventilation: 
  The subject is asked to breathe as deeply and as rapidly as he can for 15 
seconds. 
 Criteria for acceptability: 
1. Volume – time tracing shows continuous, rhythmic effort for at least 12 
seconds. 
2. End – expiratory lung volume is relatively constant. 
3. Two acceptable maneuvers are obtained; MVV values are within 10%. 
4.
 MVV is approximately equal to 35×FEV1 (17). 
Statistical analysis: 
 Pulmonary function parameters were analyzed by using statistical 
software Microsoft excel and SPSS 18.0 for windows. The statistical analysis 
was done by the Student’s t test, which was used to find the significant 
difference of pulmonary function parameters between the healthy non- diabetic 
controls and type II diabetic cases.   
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 RESULTS 
 Totally 80 subjects were participated in the study. Out of 80 
participants, 40 were type II diabetes forming the study group and the 
remaining 40 were normal subjects forming the control group. The study group 
was divided into 2 subgroups based on the duration of diabetes as 2-5 years and 
6-10 years. 
 The anthropometric, biochemical and the lung function 
parameters were analyzed by arithmetic mean and standard deviation. The 
mean values of pulmonary function parameters of the diabetics were compared 
with healthy controls using Independent Student’s t test. The pulmonary 
function parameters were correlated with duration of diabetes by using 
Pearson’s correlation coefficient test. 
 
 
 
 
 
 
 
 
 TABLE I 
                           DESCRIPTIVE STATISTICS 
 
Control & Study (n=80) 
Min Max Mean S.D 
Age 35 55 43.99 6.657 
Height 152 169 162.56 3.464 
Weight 41 91 60.85 10.713 
BMI 16.41 32.63 22.9709 3.65167 
HbA1c 2.34 6.80 4.2711 1.42972 
FEV1 44 115 86.28 14.956 
FVC 39 100 77.80 12.423 
FEV1/FVC% 91 128 116.81 7.119 
PEFR 38 168 92.40 23.799 
FEF 25-75% 44 213 131.18 34.592 
MVV 28 98 62.00 16.015 
  
 The baseline characteristics of the control and study group are 
shown in the table. 
 
 
 
 TABLE II 
Anthropometric parameters of subjects of Control and Diabetic groups 
 
 The Mean (±SD) of HbA1c of controls is 3.16 ± 0.482 and for the 
study group is 5.38 ± 1.174, shows that the controls and study group with good 
glycemic control are selected for the study. 
 
 
 
 
 
 
Control (n=40) Study (n=40) 
Min Max Mean S.D Min Max Mean S.D 
Age(years) 35 54 40.47 5.630 35 55 47.50 5.724 
Height 
(cms) 
152 169 162.38 3.814 157 169 162.75 3.111 
Weight 
(kg) 
41 91 61.68 11.796 42 81 60.03 9.588 
BMI 
(kg/m2) 
16.41 32.63 23.34 4.087 16.61 30.49 22.60 3.167 
HbA1c% 2.34 4.32 3.1607 0.483 2.40 6.80 5.38 1.174 
 TABLE III 
Pulmonary function parameters of subjects of control and diabetic groups 
 
The mean (±SD) of the pulmonary function parameters of both study group and 
control group are shown in the table.  
 
 
 
 
 
Control (n=40) Study (n=40) 
Min Max Mean S.D Min Max Mean S.D 
FEV1 64 115 91.40 11.236 44 115 81.15 16.523 
FVC 59 100 81.85 9.211 39 100 73.75 13.933 
FEV1/FVC
% 91 126 117.05 7.250 94 128 116.58 7.071 
PEFR 59 168 98.85 21.996 38 153 85.95 24.045 
FEF25-75% 85 212 136.73 26.056 44 213 125.63 41.009 
MVV 42 98 65.20 15.010 28 96 58.80 16.530 
 TABLE IV 
Comparison of pulmonary function tests parameters between the controls 
and type II diabetes  
(* P value less than 0.05 was considered to be statistically significant) 
The mean (±SD) of FEV1 for the control group are 91.40±11.236 and 
for diabetic group are 81.15±16.523. It was found to be significantly reduced (P 
= 0.002).  
The mean (±SD) of FVC for the control group is 81.85±9.211and for 
diabetic group is 73.75±13.933. The mean (±SD) of PEFR for the control group 
is 98.85±21.996 and for diabetic group is 85.95±24.045. The mean values of 
FVC and PEFR are found to be reduced in diabetic group when compared to 
controls and are statistically significant. 
PARAMETER 
Control group 
(n =40) 
Diabetic group 
(n = 40) 
P value 
FEV1 91.40±11.236 81.15±16.523 0.002* 
FVC 81.85±9.211 73.75±13.933 0.003* 
FEV1/FVC% 117.05±7.250 116.58±7.071 0.768 
PEFR 98.85±21.996 85.95±24.045 0.014* 
FEF 25-75% 136.73±26.056 125.63±41.009 0.152 
MVV 65.20±15.010 58.80±16.530 0.074 
  The mean (±SD) of FEV
and for diabetic group is 116.58±7.071. The mean (±SD) of FEF
control group is 136.73±26.056 and for diabetic group is 125.63±41.009. The 
mean (±SD) of MVV for the control group is 65.20±15.010 and for diabetic 
group is 58.80±16.530.
The mean values of 
diabetic group when compared with 
significant. 
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 TABLE V 
Comparison of pulmonary function parameter based on duration of 
diabetes mellitus between 2-5 years. 
Parameters Group I  
(n=40) 
Mean ± SD 
Group II  
(n=26) 
Mean ± SD 
P value 
FEV1 91.40±11.236 86.46±15.73       0.18 
FVC 81.85±9.211 78.23±12.99 0.19 
FEV1/FVC% 117.05±7.250 117.62±6.25 0.75 
PEFR 98.85±21.996 91.65±18.36 0.17 
FEF 25-75% 136.73±26.056 135.08±39.84 0.84 
MVV 65.20±15.010 63.88±15.35 0.73 
 
The mean ± SD of FEV1 of diabetics with duration of 2-5yrs was 
86.46±15.73 and found to be reduced when compared with the controls, but not 
statistically significant (P = 0.18) .  
The mean ± SD of FVC of diabetics in group II was 78.23±12.99. When 
compared with the control group, it was not significantly reduced. 
The mean ± SD of FEV1/FVC % of diabetics in group II was 
117.62±6.25 and for the control group was 117.05±7.250. The P = 0.75, which 
was not statistically significant. 
 
 Similarly the mean values of 
(135.08±39.84) and MVV (
when compared with control group but not statistically significant.
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 TABLE VI 
 
Comparison of pulmonary function parameter based on duration of 
diabetes mellitus between 6-10 years. 
 
 
The mean (±SD) duration of disease for diabetic patients was 8.64 ± 
1.23 years.  
The mean (±SD) of FEV1, FVC and MVV of study group having 
diabetes for 6-10years showed a highly significant reduction (P = 0.001) when 
compared with the control group. 
 
Parameters 
Group I  
(n=40) 
Mean ± SD 
Group III  
(n=14) 
Mean ± SD 
 
P value 
 
FEV1 
 
91.40±11.236 
 
71.28±12.29 
 
< 0.001* 
 
FVC 
 
81.85±9.211 
 
65.428±10.97 
 
< 0.001* 
 
FEV1/FVC % 
 
117.05±7.250 
 
114.64±7.80 
 
0.30 
 
 
PEFR 
 
98.85±21.996 
 
75.35±28.49 
 
0.003* 
 
FEF 25- 75% 
 
136.73±26.056 
 
108.07±35.54 
 
0.003* 
 
MVV 
 
65.20±15.010 
 
49.36±13.66 
 
0.001* 
The mean (±SD) 
years was 114.64±7.80
0.30). 
 
FIGURE 7: Comparison of pulmonary function parameter based on 
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 TABLE VII 
 
Comparison of pulmonary function parameter based on duration of 
diabetes mellitus between 2-5years and 6-10 years. 
 
 
The mean values of pulmonary function parameters of the diabetic 
group II and III are compared based on the duration. The mean (±SD) values of 
FEV1, FVC, PEFR, FEF 25- 75% and MVV of type II diabetics with duration 6-10 
years was found to be reduced when compared with diabetics of 2-5 years 
duration and it was found to be statistically significant. 
 
Parameters 
Group II  
(n=16) 
Mean ± SD 
Group III  
(n=14) 
Mean ± SD 
 
P value 
FEV1 86.46±15.73 71.28±12.29 0.004* 
FVC 78.23±12.99 65.428±10.97 0.004* 
FEV1/FVC % 117.62±6.25 114.64±7.80 0.21 
PEFR 91.65±18.36 75.35±28.49 0.04* 
FEF 25- 75% 135.08±39.84 108.07±35.54 0.045* 
MVV 63.88±15.35 49.36±13.66 0.006* 
The mean (±SD)
and of group II was117.62±6.25
significant. 
 
FIGURE 8: Comparison of pulmonary function parameter
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 TABLE VIII 
Correlation between duration of diabetes and the parameters of lung 
function 
 
The lung function parameters FEV1, FVC and MVV showed a 
significant negative correlation with the duration of diabetes whereas 
FEV1/FVC %, PEFR, FEF 25-75% showed negative correlation but not 
significantly. 
 
 
 
 
 
Parameter Pearson 
correlation 
P value - 
sig (2 tailed) 
 
FEV1 -0.0368 0.022 S 
FVC -0.3478 0.028 S 
FEV1/FVC -0.1301 0.423 NS 
PEFR -0.3055 0.055 NS 
FEF25- 75% -0.2935 0.066 NS 
MVV -0.4843 0.001 S 
Figure 9: Correlation between duration of diabetes and FEV
           Graph shows Negative correlation of FEV
diabetes. It is found to be statistically significant.
Figure 10: Correlation between duration of diabetes and FVC
 Graph shows Negative correlation o
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Figure 14: Correlation between duration of diabetes and MVV
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TABLE IX 
pulmonary function in the diabetes 
group and control group 
Control group (n = 40) Diabetic  group (n = 40)
9 
8 
1 
                 
, 10 of type II diabetes had 
restrictive
19%
24%
B
diabetic obstructive
 
30 
17 
13 
 
. 
57%
restrictive
 pulmonary function. 17 subjects with type II diabetes had restrictive lung 
disease and 13 had obstructive lung disease while 8 of the controls had 
restrictive lung disease and 1 had obstructive lung disease. 
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 DISCUSSION 
 Type II diabetes mellitus is the most common form of diabetes. It 
is one of the major causes of morbidity and mortality (47).  
 Diabetes is a systemic disease that produces changes in the 
structure and function of several tissues, particularly of the connective tissues 
due to microvascular and macrovascular damage that include cardiovascular 
disease, nephropathy, retinopathy and neuropathy. Since the lungs have 
abundant connective tissue, it raises the possibility that lung is also a target 
organ in diabetes (42). 
 Histological evidence of pulmonary abnormalities has included 
alterations in the ultra structure of granular pneumocytes in the interalveolar 
septum of non-ciliated bronchiolar epithelial cells and of collagen and elastin in 
the alveolar wall. 
 Post-mortem studies on diabetic patients have shown the 
thickening of alveolar epithelial and pulmonary capillary basal laminae, 
centrilobular emphysema and pulmonary angiopathy (34). 
   The pulmonary function tests are important to assess the 
respiratory function of a person. The association of reduced lung function and 
diabetes has been described many years (32). 
 In this study, the pulmonary function of type II diabetic patients 
are compared with healthy subjects. 
  In the present study the age group of the subjects was between 
35-55 years. The mean values of anthropometric parameters – height, weight 
and BMI were not compared between the control and diabetic group. Sreeja et 
al reported that there was no statistically significant difference in the 
anthropometric profiles of patients (27). Similarly Asanuma et al also observed 
that there was no significant difference in the anthropometric profiles between 
male diabetics and controls.  
 In the present study,the Mean (±SD) of HbA1c of controls is 3.16 
± 0.482 and for the study group is 5.38 ± 1.174. This shows that the controls 
and study group with good glycemic control are selected for the study. HbA1c 
reflects the glycemic control only for the past 2-3 months, a duration which 
may not be long enough to impact an effect on lung function (35). 
  In their study Davis Timothy ME et al explained that HbA1c is 
relatively short term marker of glycemic control and the impaired lung function 
could still be present in diabetes. But the duration of glycemic exposure is more 
important than its magnitude (38). 
Effect of type II diabetes onFEV1and FVC: 
  In the present study the values of FEV1and FVC are significantly 
reduced in type II diabetic patients when compared to healthy controls. These 
findings were consistent with findings of T.M.E Davis et al (38) and Davis et al 
(26) study. 
  Meo et al also supported our findings, that in normal healthy non 
smokers after the age of 35 years, the expected decline in lung function (FEV1) 
is 25-30 ml/yr, whereas in diabetics, the decline is 71 ml/yr. 
 The reduced FVC was due to increase in the cross-linkage 
formation between polypeptides of collagen in pulmonary connective tissue. 
This is responsible for the restrictive pattern of pulmonary function (49). The 
results of this study were in agreement with those of Sanjeev et al (2) and 
Maurizio et al (5) study. 
 The results of our study agreed with that of Yeh et al (45). They 
reported that adults with impaired FVC (% predicted) had various features of 
insulin resistance. The main suggestion of their study was that impaired lung 
function (FEV1 and FVC) deserves high attention as an emerging novel risk 
factor for type II diabetes. 
Effect of type II diabetes onFEV1/ FVC%: 
 FEVI/FVC ratio is a more sensitive indicator of airway 
obstruction than FVC or FEV1 alone. In the present study, the FEV1/FVC ratio 
did not show any significant change in diabetics when compared with controls. 
This shows restrictive type of pulmonary impairment as evidenced by 
significant reduction in FEV1, FVC and normal FEV1/FVC ratio. Similar results 
were observed with the study of Agarwal et al (22), Nakajima et al (41) and Ozoh 
et al in their cross-sectional study (35). 
  Similar results in Sanjeev et al (2) study showed that there was no 
significant change in FEV1/FVC %. But FVC or FEV1 were reduced show 
restrictive type of pulmonary impairment. 
 Our findings were consistent with Wannamethee and Associates 
study (47) and showed restrictive lung function with reduced FVC, FEV1and 
normal FEV1/FVC %. 
  In the prospective analyses, Heianza et al (53) found restrictive 
lung dysfunction and the possible explanations would be hypoxia induced 
insulin resistance, chronic inflammation and low birth weight in early life 
 The explanation for restrictive type of pulmonary dysfunction 
was partially explained by inflammation, traditional and metabolic risk factors 
or by obesity and inflammation. In these individuals FEV1, FVC and total lung 
capacity are reduced, but FEV1/FVC % are usually normal (50) and this study 
results were similar to the findings in large population studies in Australia, 
Denmark and the United States (38), (33), (28). 
 But Gupta et al (54) and Sreeja et al (27) observed obstructive 
pattern of lung dysfunction and it may be early change or subclinical. 
Effect of type II diabetes on PEFR: 
 In this study, the PEFR values were reduced significantly in 
diabetics (P value - 0.014) when compared with non-diabetics. The possible 
explanation is the decrease in the force generating capacity of the expiratory 
 muscle and the reduced elastic recoiling of the lungs. These findings were 
consistent with findings of Davis et al (26) and Agarwal et al (22) study. 
 Meo et al also observed reduced PEFR in their study and stated 
that the PEFR reflects not only the lung volume and the state of airways, but it 
also shows the expiratory muscle force and persistently low PEFR represents 
the collapsing of large airways (23). 
Effect of type II diabetes on FEV25-75%: 
 In this study FEF 25-75% values were reduced among diabetics 
when compared to non-diabetics but not significantly. FEF 25-75% reflects the 
flow rate during middle 50% of FVC. It also indicates patency of the small 
airways. Reduced FEF 25-75% results from increased amounts of collagen and 
elastin in basal lamina of alveolar wall. However, low FEF 25-75% represents the 
involvement of peripheral bronchioles (23). 
 Sreeja et al (27) observed significant reduction in FEF 25-75% and 
stated that this reduction is due to a lower airway caliber and high airway 
resistance (27). 
Effect of type II diabetes on MVV: 
  In the present study the mean MVV values were lower in 
diabetics than controls but not significantly. MVV is the maximum breathing 
capacity which is decreased in diabetics due to poor respiratory muscle strength 
as a result of increased protein catabolism.  A study conducted by Meo et al (23) 
 and Keerthi et al (49) showed similar results. The reason for reduced respiratory 
muscle function may be due to neuropathy, myopathy or both (32).  
 The explanation for reduced lung functions in diabetics are due to 
biochemical alterations in the connective tissue of the lung, particularly 
collagen and elastin, as well as microangiopathy. This is due to non-enzymatic 
glycosylation of proteins induced by chronic hyperglycemia. 
 The functional abnormalities from these changes are thickening 
of the pulmonary capillary basal lamina and the alveolar epithelium, reduction 
in elastic recoil of the lung, lung volumes, and also reduced pulmonary 
capacity for the diffusion of carbon monoxide (25).  
Effect of duration of diabetes on lung function: 
 In the present study, there is no significant reduction in lung 
function parameters of diabetic subjects of duration 2-5 years when compared 
with controls. But there is a significant reduction in FEV1, FVC, FEF 25-75%, 
PEFR and MVV of diabetics of duration 6-10years when compared with non-
diabetics. Whereas no significant change was observed in FEV1/FVC % of 
diabetics of 6-10 years duration shows a restrictive type of pulmonary 
impairment.  
 Thus this study shows a strong association between the duration 
of disease and decreased pulmonary function impairment in diabetic patients. 
Our findings were also supported by Nandhini et al (42). 
  Similar observation in Kanya Kumari et al (39) study showed a 
progressive decrease in mean FVC, FEV1 and PEFR values but FEV1/FVC % 
was increased suggestive of restrictive pattern of respiratory abnormality.   
 Similarly Meo et al (23) observed that type II diabetics with longer 
than 10years showed a significant reduction in FVC, FEV1, FEF 25-75%, and 
PEFR relative to their controls but the FEV1/FVC % is normal or increased. 
This impairment shows a restrictive pattern of airway disease. 
 In the Ozoh et al study, showed similar result that the effect of 
diabetes increases on ventilatory function increases with duration of diabetes. 
The underlying mechanism of reduced ventilator function in diabetes may be 
related to inflammation. As the duration of diabetes increases the inflammatory 
process also increases leading to progressive decrease in lung function (35). 
Correlation of duration of diabetes with pulmonary function 
 In our study lung function parameters were negatively correlated 
with the duration of diabetes mellitus. FEV1 (r = - 0.0368), FVC (r = -0.3478) 
and MVV (r = -0.4843) were significantly and negatively correlated with the 
duration of diabetes mellitus. These findings were consistent with findings of 
Davis et al (26) and Timothy et al (38) study. They also suggested that the reduced 
lung volumes and air flow are due to chronic complications of type II diabetes. 
 Similar findings were observed by Banu et al (32) Mahadeva 
murthy et al (52) that respiratory parameters were negatively correlated with the 
duration of diabetes.  
  In Framingham heart study by Walter et al (51) demonstrated the 
reduced lung function with duration of diabetes. In a cross-sectional study 
Sandler et al (37) found that the degree of pulmonary dysfunction was negatively 
correlated with the duration of diabetes. Similar results are observed in the 
present study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 The result of the present study shows that there is a decrease in 
the pulmonary function in type II diabetics when compared with healthy 
controls. 
 In this study there is a restrictive type of pulmonary impairment 
in type II diabetics and as the duration of diabetes increases the restrictive lung 
impairment becomes more prominent.  
 Pulmonary function parameters are negatively correlated with the 
duration of diabetes. These findings are of importance in that they demonstrate 
the need for prevention of lung damage. 
 The pulmonary dysfunction may be one of the earliest and easily 
measurable non-metabolic alterations in diabetes. Therefore the patients with 
diabetes are suggested to undergo pulmonary function testing periodically. 
  As spirometry is much more reliable, valid and simple test, it is 
time to include the spirometer as a tool for monitoring diabetes. 
Strict glycemic control and regular breathing exercises to strengthen 
respiratory muscles is necessary to improve the pulmonary function in type II 
diabetics.  
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ANNEXURES 
 
 
 
 
 
 
 
 
 
 
 
 
 CONSENT FORM 
 
Dr.S.Suguna post graduate student in the Department of physiology, 
Thanjavur Medical College, Thanjavur is doing a study on pulmonary 
functions tests in Type II Diabetes Mellitus. The procedures have been 
explained to me clearly. I understand that there are no risks involved in the 
above procedure. I hereby give my consent to participate in this study. The data 
obtained here may be used for research and publication. 
 
 
Signature: 
 
Name: 
 
Place: 
 
 
 
 
 PROFORMA 
 
TOPIC:  A study of pulmonary function test in type II diabetes mellitus 
-Spirometry based – by Dr.S.Suguna. 
 NAME OF THE PATIENT / CONTROL:                                                  
 AGE:                                                      SEX: 
ADDRESS:                                          OCCUPATION: 
PRESENT HISTORY:     
                       H/o cough with expectoration/hemoptysis/ recent surgery & MI. 
PAST HISTORY:     
                           H/o asthma, hypertension, myocardial infarction, tuberculosis. 
PERSONAL HISTORY:    
                           H/o smoking, alcoholic, tobacco & betel nut chewer 
FAMILY HISTORY :     
                            H/o asthma  , tuberculosis , hypertension  , diabetes.  
    OCCUPATIONAL HISTORY: 
                          H/o exposure to cotton dust, smokes. 
    DIABETIC HISTORY:  
                                    Duration – 
                                      Taking oral hypoglycemic drugs - 
 
 
 
 
 
 
 GENERAL EXAMINATION:  
 
         Height:                            Weight:                        BMI:    
                                     
         Anemia:                           clubbing:                     pedal edema: 
           Cyanosis:                         jaundice:                     lymphadenopathy: 
           Skeletal deformity: 
 
VITAL SIGNS: 
             Pulse rate:                                     Respiratory rate: 
  
             Blood pressure:                             Temperature: 
 
Examination of cardiovascular system: 
 
 
Examination of respiratory system: 
 
 
Examination of abdomen: 
 
 
Examination of nervous system: 
 
 
BLOOD INVESTIGATION : 
 
     Hb:                                                                     Serum creatinine: 
     Blood sugar – fasting:                                        Blood urea:   
  Blood sugar–postprandial:                                 Urine sugar: 
      HbA1c:                                                               Urine albumin                                                   
                                                  
 
                    
 
 PULMONARY FUNCTION TEST 
 
 
 
 
 
 
 
 
PARAMETERS PREDICTED 
VALUE 
SUBJECT’S 
BEST VALUE 
PREDICTED    
% 
    FVC    
    FEV1    
    FEV1/FVC    
    FEV
 (25%-75%)    
    FEV25%    
    FEV50%    
    FEV75%    
    PEFR    
    MVV    
    VT    
    SVC    
 ABBREVIATIONS 
 
DM                                           -   Diabetes Mellitus. 
HbA1c
                                 
             -   Glycated Hemoglobin. 
AGEs                                        -   Advanced Glycation End Products. 
PFT                                           -   Pulmonary Function Test. 
VC                                            -   Vital Capacity. 
FVC                                          -   Forced Vital Capacity. 
FEV1                                            -   Forced Expiratory Volume in First Second. 
PEFR                                         -   Peak Expiratory Flow Rate. 
MEFV                                       -   Maximum Expiratory flow volume. 
MVV                                         -   Maximum Voluntary Ventilation. 
TLC                                           -   Total Lung Capacity. 
RV                                             -   Residual Volume. 
 
 
 
 PULMONARY FUNCTION PARAMETERS FOR CONTROL GROUP 
S.no AGE 
(yrs) 
SEX HEIGHT 
(cm) 
WEIGHT 
(kg) 
BMI HbA1C 
% 
FEV1 FVC FEV1/FVC% PEFR FEF 
25-75% 
MVV 
1 35 F 160 54 21.09 3.5 80 83 101 92 85 66 
2 38 F 152 53 22.94 3.8 93 88 110 118 113 55 
3 41 F 162 77 29.34 4.1 94 81 124 73 124 76 
4 35 F 164 58 21.56 2.5 72 62 122 70 115 42 
5 54 M 166 65 23.59 2.7 64 73 91 84 125 46 
6 47 M 166 58 21.05 3.4 106 94 118 107 168 98 
7 43 M 158 74 29.64 2.9 104 92 119 93 152 58 
8 44 M 164 60 22.31 3 89 82 113 104 139 52 
9 40 M 161 69 26.62 2.7 93 80 121 129 212 58 
10 40 M 165 58 21.30 2.5 88 85 108 80 101 68 
11 35 F 168 60 21.26 3.1 97 98 104 106 122 68 
12 38 F 158 46 18.43 3.6 99 87 120 98 148 48 
13 35 M 169 74 25.91 2.8 91 86 110 87 133 45 
14 44 M 167 76 27.25 3.5 91 76 125 103 170 68 
15 35 M 158 41 16.42 3.1 77 67 121 83 130 53 
16 51 M 160 42 16.41 3.8 100 83 126 110 170 90 
17 35 M 161 55 21.22 2.9 76 71 114 59 89 42 
18 35 M 161 52 20.06 2.3 95 81 123 74 117 75 
19 36 F 158 65 26.04 3.4 110 95 121 95 138 43 
20 35 M 165 52 19.10 2.8 96 82 122 117 171 87 
 S.no AGE 
(yrs) 
SEX HEIGHT 
(cm) 
WEIGHT 
(kg) 
BMI HbA1C 
% 
FEV1 FVC FEV1/FVC% PEFR FEF 
25-75% 
MVV 
21 38 F 163 60 22.58 4.3 88 80 116 101 129 70 
22 39 M 163 56 21.08 3.2 105 90 123 102 170 50 
23 37 M 163 81 30.49 2.6 90 77 122 83 151 76 
24 44 F 161 63 24.30 2.4 88 82 114 99 118 49 
25 39 F 158 46 18.43 2.9 86 81 112 81 112 61 
26 45 F 155 56 23.31 3.6 105 92 122 118 135 74 
27 38 F 162 76 28.96 2.5 101 87 122 143 145 61 
28 44 M 165 51 18.73 2.8 71 59 126 81 138 65 
29 40 F 158 58 23.23 3.2 89 82 115 111 94 79 
30 51 F 162 52 19.81 3.7 92 85 115 82 117 77 
31 35 F 160 67 26.17 3.1 94 83 119 137 132 65 
32 44 M 161 45 17.36 3.4 115 100 119 137 132 65 
33 36 F 159 66 26.11 3.1 94 81 121 168 141 78 
34 38 M 164 58 21.56 2.9 85 71 124 99 159 60 
35 54 M 167 91 32.63 3 100 85 122 91 160 93 
36 38 M 166 69 25.04 3.5 97 85 119 94 152 74 
37 35 M 166 60 21.77 3.8 80 74 111 91 125 44 
38 40 M 165 69 25.34 3.2 79 73 112 76 114 66 
39 37 M 166 66 23.95 2.7 78 68 119 90 164 89 
40 51 M 168 88 31.18 3.6 104 93 116 88 159 74 
 
 PULMONARY FUNCTION PARAMETERS FOR DIABETIC GROUP 
 
S.no AGE
(yrs) 
SEX HEIGHT 
(cms) 
WEIGHT 
(kg) 
BMI HbA1C 
% 
DURATION 
(yrs) 
FEV1 FVC FEV1/
FVC% 
PEFR FEF
25-
75% 
MVV 
1 46 M 167 70 25.10 6.1 10 94 78 126 109 166 56 
2 45 M 169 62 21.71 6.5 5 110 91 126 95 193 55 
3 40 M 163 66 24.84 6.8 6 72 68 111 74 107 64 
4 54 M 164 66 24.54 6.5 9 44 39 118 51 59 31 
5 47 F 163 48 18.07 4.5 5 98 89 118 100 108 45 
6 55 F 157 47 19.07 4.86 8 61 58 113 64 83 28 
7 48 F 162 56 21.34 5.86 8 73 83 94 77 117 51 
8 46 F 158 57 22.83 5.4 4 57 55 111 111 71 45 
9 52 M 164 71 26.40 5.12 5 103 84 128 98 189 61 
10 55 M 164 59 21.94 6.01 8 78 65 124 84 164 79 
11 36 F 158 53 21.23 6.1 10 89 77 121 153 149 57 
12 52 M 164 62 23.05 5 3 82 73 118 79 121 50 
13 50 F 160 62 24.22 4.57 10 75 66 116 66 103 52 
14 50 M 164 59 21.94 5.67 5 86 96 117 79 132 70 
15 35 F 159 61 24.13 5.67 2 78 71 115 117 113 65 
16 49 M 165 75 27.55 5.2 5 97 99 103 80 149 78 
17 42 M 167 56 20.08 2.4 2 111 100 116 119 161 80 
18 37 M 168 78 27.64 4.33 3 90 80 117 94 147 81 
19 40 M 167 68 24.38 2.94 2 91 78 121 113 197 71 
20 36 F 163 81 30.49 6.69 3 79 75 110 71 104 74 
 S.no AGE
(yrs) 
SEX HEIGHT 
(cms) 
WEIGHT 
(kg) 
BMI HbA1C 
% 
DURATION 
(yrs) 
FEV1 FVC FEV1/
FVC% 
PEFR FEF
25-
75% 
MVV 
21 47 M 166 75 27.22 6.43 3 97 82 123 80 159 64 
22 55 F 161 56 21.60 5.83 10 71 70 108 53 77 47 
23 55 F 159 49 19.38 3.8 4 95 89 116 84 135 66 
24 47 M 163 55 20.70 6.67 2 88 81 113 95 122 66 
25 55 F 159 42 16.61 6.17 8 66 54 119 45 76 36 
26 50 F 162 72 27.43 6.49 5 80 74 116 68 114 54 
27 48 F 161 63 24.30 6.31 3 63 56 123 63 102 76 
28 43 F 166 62 22.50 4 3 73 64 124 139 133 45 
29 51 M 166 64 23.23 4.26 2 115 95 126 108 213 89 
30 50 M 165 56 20.57 3 2 80 73 115 95 95 53 
31 46 M 163 55 20.70 4.83 4 88 75 124 103 182 78 
32 46 M 167 66 23.67 4.76 2 93 83 118 92 159 96 
33 52 F 159 43 17.01 3.7 4 77 74 112 71 100 36 
34 50 F 159 52 20.57 4.61 3 75 72 111 71 108 54 
35 49 F 161 48 18.52 6.7 4 47 47 109 71 44 38 
36 46 M 164 72 26.77 6.39 4 95 78 128 87 161           38 
37 55 F 159 48 18.99 5.71 8 56 56 107 38 59 35 
38 48 F 162 56 21.34 6.68 7 71 66 115 82 141 56 
39 52 F 161 57 21.99 6 10 81 74 119 94 127 59 
40 40 F 161 53 20.45 6.7 9 67 62 114 65 85 40 
 
